Retinoic acid syndrome in acute promyelocytic leukemia.
Retinoic acid syndrome in acute promyelocytic leukemia.
复制标题
DOI：
--
复制
发表时间：
1997-04
影响因子：
--
通讯作者：
D. Sentero;J. Hosenpud
中科院分区：
文献类型：
--
作者：
D. Sentero;J. Hosenpud
全反式视黄酸（ATRA）已成功用于诱导急性早幼粒细胞白血病（APL）患者的缓解。与标准诱导化疗相比，其总体毒性显着降低；然而，它与被称为“视黄酸综合征”的潜在致命症状复合体的高发生率有关。本报告描述了一名 APL 患者，尽管正在接受白细胞增多症治疗，但在开始 ATRA 诱导治疗几周后出现了该综合征。该病例说明了该综合征的典型特征及其对皮质类固醇治疗的显着反应。
All-trans retinoic acid (ATRA) has been used successfully in inducing remission in patients with acute promyelocytic leukemia (APL). Its overall toxicity is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as "retinoic acid syndrome." This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis. The case illustrates the classic features of the syndrome and its dramatic response to corticosteroid treatment.